Trial · NCT03167242
Results by group174
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 174
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | 46 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 Day | 45 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 Days | 47 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 Days | 47 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 Days | 44 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 Days | 42 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part A - Cohort 7: Coartem | 25 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | 37 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part B - Cohort 2: KAF 400 mg and LUM 960 mg QD for 2 Days | 42 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part B - Cohort 3: KAF 400 mg and LUM 960 mg QD for 3 Days | 38 | Participants | ||
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 | Part B - Cohort 4: Coartem | 21 | Participants | ||
| PK Run-in: Area Under the Blood Concentration-time Curve Over the Last 24 Hours After Treatment Dose (AUC0-24h) of KAF156 | PK Run-in Cohort: KAF 200 mg and LUM 960 mg QD for 1 Day | 5.35 | Geometric Coefficient of Variation 34.8 | hours*μg/mL | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | Day 14 post first dose | 49 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 2: KAF 800 mg and LUM 960 mg QD for 1 Day | Day 14 post first dose | 47 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 3: KAF 400 mg and LUM 960 mg QD for 2 Days | Day 14 post first dose | 51 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 4: KAF 200 mg and LUM 480 mg QD for 3 Days | Day 14 post first dose | 53 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 5: KAF 400 mg and LUM 480 mg QD for 3 Days | Day 14 post first dose | 50 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 6: KAF 400 mg and LUM 960 mg QD for 3 Days | Day 14 post first dose | 51 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part A - Cohort 7: Coartem | Day 14 post first dose | 27 | Participants | |
| Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Uncorrected Adequate Clinical and Parasitological Response (ACPR) | Part B - Cohort 1: KAF 400 mg and LUM 960 mg QD for 1 Day | Day 14 post first dose | 51 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03167242/results